Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 9:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 81 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Overactive Bladder With Urinary Incontinence Clear all
Completed Phase 3 Interventional Results available

A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB)

NCT03492281
View directory record Official record
Conditions
Overactive Bladder
Interventions
vibegron, Vibegron placebo, Tolterodine Tartrate ER, Tolterodine placebo
Drug
Lead sponsor
Urovant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
1,530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
191
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Huntsville, Alabama + 155 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Sep 9, 2026, 9:48 PM EDT
Completed Phase 2 Interventional Results available

URO-902 in Female Subjects With Overactive Bladder and Urge Urinary Incontinence

NCT04211831
View directory record Official record
Conditions
Overactive Bladder With Urge Urinary Incontinence
Interventions
URO-902, Placebo
Drug
Lead sponsor
Urovant Sciences GmbH
Industry
Eligibility
40 Years to 79 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
20
States / cities
Mobile, Alabama • Tucson, Arizona • Laguna Hills, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2023 · Synced Sep 9, 2026, 9:48 PM EDT
Completed Phase 3 Interventional Results available

This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder

NCT01972841
View directory record Official record
Conditions
Urinary Bladder Overactive, Urinary Bladder Diseases\Urologic Diseases, Overactive Bladder, Urgency Incontinence
Interventions
Solifenacin succinate, Mirabegron, Placebo to match solifenacin succinate, Placebo to match mirabegron
Drug
Lead sponsor
Astellas Pharma Europe B.V.
Industry
Eligibility
18 Years and older
Enrollment
3,527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
121
States / cities
Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 96 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Sep 9, 2026, 9:48 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Higher Neural Changes Following Anticholinergic, Beta 3 Agonist, or Placebo in Patients With Overactive Bladder

NCT03817931
View directory record Official record
Conditions
Overactive Bladder, Dementia, Lower Urinary Tract Symptoms, Incontinence, Urge
Interventions
Anticholinergic, Beta-3 Agonists, Adrenergic, Functional magnetic resonance imaging (fMRI), Rey Auditory Verbal Learning Test (RAVLT)
Drug · Diagnostic Test
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
2
States / cities
Houston, Texas • Temple, Texas
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Sep 9, 2026, 9:48 PM EDT
Completed No phase listed Observational Results available

Central Nervous System Changes Following OnabotulinumtoxinA Injection in the Bladder

NCT03033355
View directory record Official record
Conditions
Multiple Sclerosis, Lower Urinary Tract Symptoms, Neurogenic Bladder, Detrusor, Overactive, Urge Incontinence
Interventions
Intra-detrusor injection of Onabotulinumtoxin-A
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 4, 2025 · Synced Sep 9, 2026, 9:48 PM EDT
Not listed No phase listed Observational

Treatment of Overactive Bladder With a Digital Conversational Agent: the MOTIVATION Study

NCT04853849
View directory record Official record
Conditions
Overactive Bladder, Urge Incontinence, Pelvic Floor Disorders
Interventions
Not listed
Lead sponsor
Renalis
Industry
Eligibility
40 Years and older · Female only
Enrollment
50 participants
Timeline
2021 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 9, 2021 · Synced Sep 9, 2026, 9:48 PM EDT
Completed Phase 3 Interventional Results available

Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence

NCT00910520
View directory record Official record
Conditions
Overactive Bladder
Interventions
onabotulinumtoxinA, normal saline
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
548 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Laguna Hills, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2013 · Synced Sep 9, 2026, 9:48 PM EDT
Completed Phase 1 Interventional

Safety and Tolerability of TAR-302-5018 in Subjects With Idiopathic Overactive Bladder

NCT03109379
View directory record Official record
Conditions
Idiopathic Overactive Bladder With Urinary Incontinence
Interventions
Trospium-Releasing Intravesical System (TAR-302-5018)
Drug
Lead sponsor
Taris Biomedical LLC
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
12
States / cities
Tucson, Arizona • San Diego, California • Pompano Beach, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2020 · Synced Sep 9, 2026, 9:48 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Cycling Study With the Axonics System

NCT05543382
View directory record Official record
Conditions
Overactive Bladder Syndrome, Urinary Urge Incontinence, Sacral Neuromodulation
Interventions
Axonics System
Device
Lead sponsor
Axonics, Inc.
Industry
Eligibility
21 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
6
States / cities
Naples, Florida • New Orleans, Louisiana • Cleveland, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Sep 9, 2026, 9:48 PM EDT
Completed Phase 4 Interventional

Effect of Detrol LA on Overactive Bladder Symptoms, Sexual Quality of Life and Sexual Function in Women

NCT00143481
View directory record Official record
Conditions
Urinary Incontinence
Interventions
Tolterodine ER 4mg QD
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
58
States / cities
Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Sep 9, 2026, 9:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect Of Fluconazole On Pharmacokinetics Of Fesoterodine In Healthy Subjects

NCT00911235
View directory record Official record
Conditions
Overactive Bladder With Symptoms of Frequency, Urgency, and Urge Urinary Incontinence
Interventions
Fesoterodine, fesoterodine plus fluconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 31, 2011 · Synced Sep 9, 2026, 9:48 PM EDT
Completed Phase 4 Interventional

Detrol LA In Men With Overactive Bladder.

NCT00282932
View directory record Official record
Conditions
Overactive Bladder (OAB)
Interventions
Detrol LA
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
40 Years and older · Male only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
11
States / cities
Anaheim, California • La Mesa, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Sep 9, 2026, 9:48 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

A Practice-Based Intervention To Improve Care for a Diverse Population Of Women With Urinary Incontinence

NCT05534412
View directory record Official record
Conditions
Urinary Incontinence
Interventions
Academic Detailing, Electronic Clinical Decision Support, APP Co-management, Electronic Referral
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
1,600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
4
States / cities
La Jolla, California • Los Angeles, California • Torrance, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 9, 2026, 9:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Percutaneous Nerve Evaluation With Fluoroscopy Versus Without

NCT02677753
View directory record Official record
Conditions
Overactive Bladder, Urinary Incontinence, Fecal Incontinence
Interventions
Fluoroscopy
Radiation
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older · Female only
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 8, 2020 · Synced Sep 9, 2026, 9:48 PM EDT
Completed Phase 4 Interventional Results available

Trospium Chloride XR in Obese Female Patients With Overactive Bladder

NCT00932022
View directory record Official record
Conditions
Obesity, Overactive Bladder, Incontinence
Interventions
Trospium Chloride, Extended Release (XR), placebo
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
La Mesa, California
Source: ClinicalTrials.gov public record
Updated Jan 20, 2013 · Synced Sep 9, 2026, 9:48 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Solifenacin Succinate Versus Placebo in Inner City Women Ages 20-45 With Overactive Bladder

NCT00773552
View directory record Official record
Conditions
Urinary Urge, Urge Incontinence, Overactive Bladder
Interventions
solifenacin succinate, placebo
Drug
Lead sponsor
Stamford Hospital
Other
Eligibility
20 Years to 45 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
2
States / cities
Stamford, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 5, 2016 · Synced Sep 9, 2026, 9:48 PM EDT
Completed Phase 4 Interventional

Effect and Safety Of Detrol LA In Men With Overactive Bladder Symptoms With Or Without Bladder Outlet Obstruction

NCT00147654
View directory record Official record
Conditions
Urinary Incontinence
Interventions
Tolterodine ER 4 mg QD, Tamsulosin 0.4 mg QD
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
40 Years and older · Male only
Enrollment
830 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
95
States / cities
Birmingham, Alabama • Homewood, Alabama • Tucson, Arizona + 92 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Sep 9, 2026, 9:48 PM EDT
Withdrawn Phase 2 Interventional

Autologous Neo-Bladder Construct in Non-Neurogenic Overactive Bladder and Urge Predominant Incontinence

NCT00594139
View directory record Official record
Conditions
Overactive Bladder
Interventions
Autologous neobladder construct
Biological
Lead sponsor
Tengion
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 7, 2018 · Synced Sep 9, 2026, 9:48 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Bringing Simple Urge Incontinence Diagnosis & Treatment to Providers (BRIDGES)

NCT00862745
View directory record Official record
Conditions
Urge Urinary Incontinence, Overactive Bladder
Interventions
Fesoterodine, Matching Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Female only
Enrollment
645 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
13
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2011 · Synced Sep 9, 2026, 9:48 PM EDT
Completed Not applicable Interventional

Vitamin D Supplementation in Older Adults With Urinary Incontinence

NCT01971801
View directory record Official record
Conditions
Urinary Incontinence, Vitamin D Deficiency
Interventions
Vitamin D3 50,000 IU, Placebo
Dietary Supplement · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
50 Years and older · Female only
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 8, 2018 · Synced Sep 9, 2026, 9:48 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Over Active Bladder Patients Having Sling Surgery

NCT00852696
View directory record Official record
Conditions
Overactive Bladder
Interventions
Solifenacin, Placebo
Drug · Other
Lead sponsor
Cleveland Clinic Florida
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Sep 9, 2026, 9:48 PM EDT
Not listed Not applicable Interventional

Comparison of Craniosacral Therapy vs Pelvic Floor Physical Therapy

NCT03213522
View directory record Official record
Conditions
Multiple Sclerosis, Bladder Dysfunction, Urinary Incontinence, Overactive Bladder
Interventions
Pelvic Floor Physical Therapy, Craniosacral Therapy
Procedure
Lead sponsor
CentraState Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Freehold, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 10, 2017 · Synced Sep 9, 2026, 9:48 PM EDT
Recruiting Phase 2Phase 3 Interventional

Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms

NCT05878951
View directory record Official record
Conditions
Urinary Incontinence, Overactive Bladder Syndrome, Overactive Bladder, Urologic Diseases
Interventions
OnabotulinumtoxinA
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 89 Years · Male only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 9, 2026, 9:48 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of AGN-214868 in Patients With Idiopathic Overactive Bladder and Urinary Incontinence

NCT01157377
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
AGN-214868, AGN-214868 placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 75 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 18, 2014 · Synced Sep 9, 2026, 9:48 PM EDT